With an eye towards the IPO in October this year, Rapid Response Revival Research Limited has executed a mandate with a US Investment Bank, to be a lead manager and underwriter to the issue. This mandate includes working with the company to raise capital in anything that private capital raises is required in the lead up to the IPO.
The IB is the No.1 ranked US bank in Healthcare Investment Banking in the US, having completed transactions in over 200 companies in the last 2 years.
About Rapid Response Revival Research Limited
Rapid Response Revival are the innovators behind the CellAED® defibrillator technology – transforming everyday people into heroes.
Sudden Cardiac Arrest (SCA) has an extremely high death rate and is a leading cause of death globally, accounting for more deaths than many cancers, influenza, car accidents and house fire deaths combined. Anyone can suffer from SCA, regardless of age, gender or fitness level – including children. The current survival rate is just 2-11%.
The CellAED® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.